Palvella Aims for 2026 NDA Submission After Positive Phase 3 Data
Event summary
- Palvella reported positive Phase 3 SELVA trial results for QTORIN™ rapamycin in microcystic lymphatic malformations, meeting primary and secondary endpoints.
- The company plans to submit a New Drug Application (NDA) for QTORIN™ rapamycin in the second half of 2026.
- Palvella raised $230 million in February 2026, bringing pro forma cash to approximately $274 million as of December 31, 2025.
The big picture
Palvella is positioning itself as a leader in rare disease biopharmaceuticals, targeting conditions with no FDA-approved therapies. The successful Phase 3 trial results and substantial financing strengthen its path to potential approval and commercialization of QTORIN™ rapamycin. The company's focus on expanding its pipeline and strengthening its leadership team underscores its ambition to become a key player in the rare disease space.
What we're watching
- Regulatory Timing
- Whether the FDA will expedite review given Breakthrough Therapy and Orphan designations.
- Commercial Readiness
- The pace at which Palvella can prepare for a standalone U.S. commercial launch.
- Pipeline Expansion
- How quickly Palvella can advance QTORIN™ rapamycin into additional indications and new product candidates.